QC
BIOA

Quadrature Capital’s BioAge Labs BIOA Stock Holding History

Quadrature Capital’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,769
Closed -$222K – 1949
2025
Q4 		$222K Buy
16,769
+6,035
+56% +$53.5K ﹤0.01% 945
2025
Q3 		$63.1K Buy
+10,734
New +$50.3K ﹤0.01% 939

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Quadrature Capital's BIOA Position: Q1 2026 in Review

Quadrature Capital sold out of BioAge Labs (BIOA) in Q1 2026, closing a stake of 16,769 shares — an estimated $222K sold.

Quadrature Capital first reported a position in BIOA in Q3 2025 and held it in 2 quarters. The position peaked at $222K in Q4 2025. 144 funds tracked by Wall St. Rank hold BIOA as of Q1 2026.

  • Quadrature Capital reported no remaining BioAge Labs position as of Q1 2026 after selling out during the quarter.
  • Quadrature Capital sold 16,769 BioAge Labs shares in Q1 2026, an estimated $222K.
  • Quadrature Capital first reported a position in BioAge Labs in Q3 2025 and held it in 2 quarters.
  • Quadrature Capital's BioAge Labs position peaked at $222K in Q4 2025.
  • 144 funds tracked by Wall St. Rank held BioAge Labs as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.